Headquartered in New York City, the firm develops state-of-the-art chemical simulation software for use in pharmaceutical and biotechnology research. It empowers researchers around the globe to accomplish their goals of enhancing human health and quality of life by leveraging advanced computational techniques that transform the way chemists design compounds and materials.
The company offers products ranging from general molecular modeling programs to a full-featured suite of drug design software using ligand- and structure-based techniques. “Schrödinger has made key scientific breakthroughs in recent years in the areas of protein and ligand structure determination and potency prediction that have made a significant impact on drug discovery,” comments Dr. Ramy Farid, President, Schrödinger.
Schrödinger’s product suites include Small Molecule Drug Discovery Suite, Biologics Suite, Materials Science Suite, Discovery Informatics Suite, and PyMOL. Small Molecule Drug Discovery Suite helps in accelerating the lead discovery and also lead optimization. It comprises of a number of products such as Canvas, CombiGlide, and ConfGen. Biologics suite that features BioLuminate includes all the tools that are necessary in modeling biologics, antibodies, and proteins. It includes eight products— Desmond, Epik, MacroModel, Maestro, Prime, Protein Preparation Wizard, QSite, and SiteMap.
Schrödinger has made key scientific breakthroughs in recent years in the areas of protein and ligand structure determination and potency prediction
Schrödinger’s Materials Science Suite is a diverse set of tools for computing the structure, reactivity, and properties of chemical systems. Consisting of seven products, it enables research teams to design individual chemical structures by sketching, using a fragment library, or with tools—like the macromolecule complex builder. Discover Informatics Suite offers fast, secure, and scalable web-based tools accessible by every member of a discovery team. It consists of LiveDesign, Seurat, and Canvas products that help in data sharing and collaborative design across the entire discovery team in real time.
The company’s PyMOL product offers high-performance molecular graphics for communicating structural results. It is designed by scientists for scientists to view, share, and analyze their molecular data. PyMOL can develop images of peerless visualization quality and also deliver the flexibility of Java-based development and scalability.
Recently, the company collaborated with Pfizer to develop a computational model for important properties relevant to biotherapeutic candidates and Farid believes that the true measure of drug discovery software’s success lies in the contribution it makes to actual drug discovery programs. In future, Schrödinger plans to collaborate with more institutions to progress and enhance their solutions. “We are thrilled to work together on developing technology that could potentially be applied to pharmaceutical research,” concludes Farid.